Published in Brain Pathol on January 01, 2011
OTX2 represses myogenic and neuronal differentiation in medulloblastoma cells. Cancer Res (2012) 0.98
Subgroup-specific alternative splicing in medulloblastoma. Acta Neuropathol (2012) 0.92
Matching mice to malignancy: molecular subgroups and models of medulloblastoma. Childs Nerv Syst (2012) 0.83
MyoD is a tumor suppressor gene in medulloblastoma. Cancer Res (2013) 0.83
Complex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies: pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades and novel multitargeted therapies. Brain Pathol (2011) 0.82
Review: In vivo models for defining molecular subtypes of the primitive neuroectodermal tumor genome: current challenges and solutions. In Vivo (2012) 0.78
Effect of small nuclear ribonucleoprotein-associated polypeptide N on the proliferation of medulloblastoma cells. Mol Med Rep (2015) 0.77
Clinical, pathological, and molecular data on desmoplastic/nodular medulloblastoma: case studies and a review of the literature. Clin Neuropathol (2016) 0.75
The role of CD133+ cells in a recurrent embryonal tumor with abundant neuropil and true rosettes (ETANTR). Brain Pathol (2013) 0.75
Infratentorial medulloepithelioma with divergent differentiation: Possibly a predictor of poor outcome. J Pediatr Neurosci (2012) 0.75
The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 49.11
Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature (2002) 15.36
Medulloblastoma comprises four distinct molecular variants. J Clin Oncol (2010) 8.06
Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature (1998) 7.55
The molecular basis of Turcot's syndrome. N Engl J Med (1995) 6.65
Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol (2006) 5.96
Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One (2008) 5.86
Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet (2001) 4.48
Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol (2010) 4.48
Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res (1999) 4.26
Sporadic medulloblastomas contain PTCH mutations. Cancer Res (1997) 3.22
beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol (2005) 2.84
YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes Dev (2009) 2.58
Predisposition to atypical teratoid/rhabdoid tumor due to an inherited INI1 mutation. Pediatr Blood Cancer (2006) 2.48
Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res (1997) 2.45
Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle (2006) 2.37
Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Res (2005) 2.35
Sporadic medulloblastomas contain oncogenic beta-catenin mutations. Cancer Res (1998) 2.33
Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms. Am J Surg Pathol (2004) 2.33
Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol (2009) 2.15
Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol (2010) 2.04
Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell (2009) 1.92
Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol (2005) 1.83
Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. Am J Hum Genet (2010) 1.83
Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. Acta Neuropathol (2010) 1.82
OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. Cancer Res (2009) 1.77
Genomic amplification of orthodenticle homologue 2 in medulloblastomas. Cancer Res (2005) 1.75
Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol (2010) 1.74
Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J Clin Oncol (2010) 1.65
Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol (2004) 1.62
Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas. Cancer Res (2001) 1.60
PDGFRB is overexpressed in metastatic medulloblastoma. Nat Genet (2003) 1.46
Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res (2004) 1.45
High-resolution array-based comparative genomic hybridization of medulloblastomas and supratentorial primitive neuroectodermal tumors. J Neuropathol Exp Neurol (2006) 1.43
Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer (2001) 1.43
Chromosome abnormalities in pediatric brain tumors. Cancer Res (1988) 1.42
Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients. Clin Cancer Res (2005) 1.40
APC mutations in sporadic medulloblastomas. Am J Pathol (2000) 1.40
Ependymoblastoma: dear, damned, distracting diagnosis, farewell!*. Brain Pathol (2008) 1.40
OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomas. J Neuropathol Exp Neurol (2006) 1.39
Immunohistochemical analysis of INI1 protein in malignant pediatric CNS tumors: Lack of INI1 in atypical teratoid/rhabdoid tumors and in a fraction of primitive neuroectodermal tumors without rhabdoid phenotype. Am J Surg Pathol (2006) 1.39
C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer (2000) 1.37
MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med (2002) 1.37
Nuclear localization and mutation of beta-catenin in medulloblastomas. J Neuropathol Exp Neurol (2000) 1.34
Pediatric neuroblastic brain tumors containing abundant neuropil and true rosettes. Pediatr Dev Pathol (2000) 1.32
Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci U S A (1994) 1.27
Immunohistochemistry of INI1 expression: a new tool for old challenges in CNS and soft tissue pathology. Adv Anat Pathol (2007) 1.26
Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood. J Neurooncol (1995) 1.25
Somatic mutations in the human homologue of Drosophila patched in primitive neuroectodermal tumours. Oncogene (1997) 1.23
Embryonal tumors with abundant neuropil and true rosettes: a distinctive CNS primitive neuroectodermal tumor. Am J Surg Pathol (2009) 1.23
Structural chromosomal abnormalities in human medulloblastoma. Cancer Genet Cytogenet (1988) 1.22
Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes. Acta Neuropathol (2008) 1.20
Increased p53 immunopositivity in anaplastic medulloblastoma and supratentorial PNET is not caused by JC virus. BMC Cancer (2005) 1.19
Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91. Clin Cancer Res (2007) 1.18
Prognostic implications of chromosome 17p deletions in human medulloblastomas. J Neurooncol (1995) 1.18
N-myc and c-myc oncogenes amplification in medulloblastomas. Evidence of particularly aggressive behavior of a tumor with c-myc amplification. Tumori (1991) 1.16
Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease. Acta Neuropathol (2010) 1.15
AXIN1 mutations but not deletions in cerebellar medulloblastomas. Oncogene (2003) 1.13
Role of Wnt pathway in medulloblastoma oncogenesis. Int J Cancer (2002) 1.09
An investigation of WNT pathway activation and association with survival in central nervous system primitive neuroectodermal tumours (CNS PNET). Br J Cancer (2009) 1.08
Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. Brain Pathol (2002) 1.08
Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol (1998) 1.08
Large-cell medulloblastomas. A distinct variant with highly aggressive behavior. Am J Surg Pathol (1992) 1.08
Supratentorial primitive neuroectodermal tumors of the central nervous system frequently harbor deletions of the CDKN2A locus and other genomic aberrations distinct from medulloblastomas. Genes Chromosomes Cancer (2007) 1.05
Atypical teratoid or rhabdoid tumors: improved outcome with high-dose chemotherapy. J Pediatr Hematol Oncol (2010) 1.05
Clinical and molecular features in patients with atypical teratoid rhabdoid tumor or malignant rhabdoid tumor. Genes Chromosomes Cancer (2010) 1.02
Central nervous system primitive neuroectodermal tumors: a clinicopathologic and genetic study of 33 cases. Brain Pathol (2009) 1.01
Claudin 6 is a positive marker for atypical teratoid/rhabdoid tumors. Brain Pathol (2009) 0.98
Health and persistent functional late effects in adult survivors of childhood CNS tumours: a population-based cohort study. Eur J Cancer (2009) 0.96
From childhood to adulthood: long-term outcome of medulloblastoma patients. The Institut Curie experience (1980-2000). J Neurooncol (2009) 0.96
Genetic profiling of CNS tumors extends histological classification. Acta Neuropathol (2010) 0.94
Intense p53 staining is a valuable prognostic indicator for poor prognosis in medulloblastoma/central nervous system primitive neuroectodermal tumors. J Neurooncol (2001) 0.93
Correlation of loss of heterozygosity at chromosome 9q with histological subtype in medulloblastomas. Am J Pathol (1995) 0.93
Neurotrophin receptor TrkC predicts good clinical outcome in medulloblastoma and other primitive neuroectodermal brain tumors. Klin Padiatr (2000) 0.89
The role of INI1/hSNF5 in gene regulation and cancer. Biochem Cell Biol (2009) 0.84
Amplification and overexpression of KIT, PDGFRA, and VEGFR2 in medulloblastomas and primitive neuroectodermal tumors. J Neurooncol (2009) 0.82
Upregulation of SOX2, NOTCH1, and ID1 in supratentorial primitive neuroectodermal tumors: a distinct differentiation pattern from that of medulloblastomas. J Neurosurg Pediatr (2010) 0.81